Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 20Recurrence 5Leukemia, Myeloid, Acute 4Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Waldenstrom Macroglobulinemia 1Renal Insufficiency 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoglobulin Light-chain Amyloidosis 1Hypergammaglobulinemia 1Hodgkin Disease 1Hematologic Diseases 1Disease 1Breast Neoplasms 1

Interventions

ibrutinib 1daratumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hypergammaglobulinemia × daratumumab × Clear all
NCT03679624 2023-10-23

Daratumumab Plus Ibrutinib in Patients With WaldenstrÓ§m's Macroglobulinemia

Weill Medical College of Cornell University

Phase 2 Terminated
1 enrolled 8 charts
Lymphoid

Hypergammaglobulinemia, Waldenstrom Macroglobulinemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡